Financing channel feed

Ex­clu­sive: For­mer Mer­ck sci­en­tists raise $85M to map and drug pro­tein in­ter­ac­tions in can­cer and au­toim­mune dis­ease

Last year
Startups

Fore­site Cap­i­tal clos­es $900M sixth fund, back­ing the likes of Xaira and IPO hope­ful Alu­mis

Last year
Startups

Piv­ot­ing to ‘ADC-like’ ap­proach, Ver­sant-backed start­up gets $90M Se­ries C

Last year
R&D

ARCH backs lab in­stru­ment com­pa­ny that wants to help de­mys­ti­fy how cells talk to each oth­er

Last year
Startups

Os­car stakes its fu­ture on com­pa­nies dump­ing work­er health ben­e­fits

Last year
Health Tech

New obe­si­ty biotech Syn­tis Bio launch­es with ear­ly-stage al­ter­na­tive to GLP-1s

Last year

Alu­mis files for IPO ahead of Phase 3 stud­ies for sec­ond-gen TYK2 in­hibitor

Last year

UK medtech rais­es $100M for two-in-one uri­nary in­con­ti­nence treat­ment

Last year

Ger­man ra­dio­phar­ma nabs €188M to boost iso­tope man­u­fac­tur­ing, ad­vance can­cer pipeline

Last year
Manufacturing

Ra­dio­phar­ma­ceu­ti­cal com­pa­ny Telix aims for $202M IPO

Last year
R&D

No­vo Hold­ings’ head of Asia on in­vest­ing in ‘Chi­na for Chi­na,’ and stay­ing out of biotech (for now)

Last year
China
Pharma

Ex­clu­sive: In­spired by Spin­raza, start­up rais­es $25M for can­cer drug tar­gets cre­at­ed by al­ter­na­tive RNA splic­ing

Last year
AI

Aus­tralian life sci­ences VC Bran­don Cap­i­tal rais­es $180M for sixth fund

Last year
Startups

Rap­port Ther­a­peu­tics sets out for $122M Nas­daq de­but as IPO back­log seeks fresh air

Last year
Startups

Joe Jimenez and Mark Fish­man tar­get $400M for third fund af­ter leav­ing No­var­tis

Last year
Startups

Cin­Rx rais­es $73M to cre­ate more biotechs, fur­ther sup­port obe­si­ty drug de­vel­op­ment

Last year
Startups

New York start­up rais­es $33M for fer­til­i­ty treat­ment based on George Church’s stem cell re­search

Last year
Cell/Gene Tx

Cana­di­an biotech VC Am­pli­tude rais­es $192M sec­ond fund

Last year
Startups

Ex­clu­sive: SR One rais­es $200M+ for third fund, still with GSK sup­port

Last year

Start­up launch­es with ‘RNA sen­sor’ tech­nol­o­gy from Stan­ford and MIT to bet­ter con­trol mR­NA ther­a­pies

Last year

Grey Wolf reels in $50M to ex­pand in­to au­toim­mune dis­eases

Last year
Startups

Ver­sant has a new obe­si­ty biotech. As­traZeneca has the op­tion to buy it

Last year
Startups
Pharma

With a fresh $100M, Monte Rosa CEO de­tails plans to move sev­er­al mol­e­c­u­lar glues in­to the clin­ic

Last year

Al­tru­Bio se­cures $225M for an up­dat­ed ver­sion of its ul­cer­a­tive col­i­tis drug

Last year
Startups
First page Previous page 15161718192021 Next page Last page
A service from the Financial Times